Davis's Drug Guide
Glyxambi 25/5
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Glyxambi 25/5." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110216/all/Glyxambi_25_5.
Vallerand AHA, Sanoski CAC, . Glyxambi 25/5. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110216/all/Glyxambi_25_5. Accessed October 30, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Glyxambi 25/5. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110216/all/Glyxambi_25_5
Vallerand AHA, Sanoski CAC, . Glyxambi 25/5 [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 October 30]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110216/all/Glyxambi_25_5.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Glyxambi 25/5
ID - 110216
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110216/all/Glyxambi_25_5
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
